Quartz Partners LLC Buys Shares of 15,650 Cencora, Inc. $COR
Quartz Partners LLC recently acquired 15,650 shares of Cencora, Inc. (COR) valued at approximately $4.43 million, making it 1.5% of their portfolio. Cencora reported strong quarterly earnings with an EPS of $4.48, surpassing estimates, and revenue growth of 5.1% year-over-year. The company maintains a "Moderate Buy" consensus rating from analysts, announced a quarterly dividend of $0.60 per share, and authorized a $2 billion share buyback program.
Shepherd Financial Partners LLC Takes Position in Cencora, Inc. $COR
Shepherd Financial Partners LLC has acquired a new stake in Cencora, Inc. (NYSE:COR), purchasing 5,570 shares valued at approximately $1,576,000. Other institutional investors like Vanguard Group Inc., BlackRock Inc., and State Street Corp have also significantly adjusted their holdings in Cencora. The company recently announced a stock repurchase plan of $2.00 billion and a quarterly dividend of $0.60 per share.
Meeder Advisory Services Inc. Purchases New Stake in Cencora, Inc. $COR
Meeder Advisory Services Inc. has acquired a new stake of 5,453 shares in Cencora, Inc. (NYSE:COR), valued at approximately $1.54 million. This investment is part of a broader trend of institutional buying, with several other firms also increasing their positions in Cencora. Analysts have issued "Buy" or "Overweight" ratings for Cencora, forecasting further growth and setting an average price target of $370.85.
Foster & Motley Inc. Takes $1.50 Million Position in Cencora, Inc. $COR
Foster & Motley Inc. has acquired a new position in Cencora, Inc. (NYSE:COR) by purchasing 5,317 shares valued at approximately $1.50 million during the second quarter. This move is part of a broader trend of institutional investment in Cencora, with other major firms like BlackRock Inc. and T. Rowe Price Investment Management Inc. also increasing their stakes. The article details Cencora's stock performance, recent earnings, and analyst ratings, which currently indicate a "Moderate Buy" consensus.
McKesson (MCK) Could Be 11% Undervalued After Earnings And Buybacks
McKesson (MCK) reported its Q1 2026 earnings with increased sales but lower net income and EPS. Despite a recent share price jump and ongoing buybacks, the stock is currently considered 11.4% undervalued with a fair value of US$980.80, compared to its recent close of US$869.26. This valuation is based on improving revenue mix, higher operating margins, and a shrinking share count, though potential risks from drug pricing regulation could impact future performance.
Cardinal Health (CAH) Taps Anita Zielinski As Chief Accounting Officer
Cardinal Health (NYSE: CAH) has appointed Anita Zielinski as Chief Accounting Officer, bringing extensive financial and operational experience from her previous roles, including interim CFO at Baxter. This strategic hire aligns with Cardinal Health's ongoing transformation efforts, enhancing financial oversight and accountability, especially given the company's significant annual sales and active buyback program. Zielinski's expertise is expected to strengthen financial controls and execution amidst challenges like high debt and product recall exposure.
Cencora stock initiated at Sector Perform by RBC Capital with $330 target
RBC Capital has initiated coverage on Cencora Inc (NYSE:COR) with a Sector Perform rating and a $330 price target, noting the company's pharma-aligned platform will benefit from specialty pharma growth. While recognizing the potential from specialty drugs and biosimilar introductions, the firm also highlighted Cencora's lower gross profit margin and anticipated headwinds from IRA negotiations affecting Part B drugs. This initiation comes as Cencora recently reported strong fiscal third-quarter 2026 results, surpassing expectations and raising its full-year profit outlook.
Wealthfront Advisers LLC Buys Shares of 42,108 Cencora, Inc. $COR
Wealthfront Advisers LLC has acquired a new stake of 42,108 shares in Cencora, Inc. (NYSE:COR) during the second quarter, valued at approximately $11.9 million. This purchase is part of broader institutional investment, with 97.52% of Cencora's stock owned by institutional investors and hedge funds. The company recently reported strong quarterly earnings, beating expectations, declared a dividend, and authorized a $2 billion share repurchase program, contributing to a "Moderate Buy" consensus among analysts.
Great Lakes Advisors LLC Buys Shares of 344,507 Cencora, Inc. $COR
Great Lakes Advisors LLC has acquired a new stake of 344,507 shares in Cencora, Inc. (NYSE:COR) valued at approximately $97.5 million during the second quarter. Other institutional investors like Vanguard Group Inc., BlackRock Inc., and State Street Corp also adjusted their holdings in the company. Cencora has received a "Moderate Buy" rating from analysts, with a consensus target price of $374.25, and recently announced a stock repurchase plan of $2.00 billion and a quarterly dividend of $0.60 per share.
Danske Bank A S Invests $76.71 Million in Cencora, Inc. $COR
Danske Bank A S has acquired a new position in Cencora, Inc. (NYSE:COR), purchasing 271,081 shares valued at approximately $76.71 million during the second quarter. This investment makes Danske Bank A S an owner of 0.14% of Cencora. The article also details other institutional investor activities, insider trading, and recent financial performance, including Cencora's stock buyback program, dividend announcement, and analyst ratings.
Diversify Advisory Services LLC Buys Shares of 8,769 Cencora, Inc. $COR
Diversify Advisory Services LLC has acquired a new position in Cencora, Inc. (NYSE:COR), purchasing 8,769 shares valued at approximately $2.73 million during the second quarter. Other institutional investors like BlackRock Inc. and T. Rowe Price Investment Management Inc. also significantly adjusted their holdings in Cencora. Analysts currently rate Cencora with a "Moderate Buy" consensus and an average target price of $374.25.
Cencora stock initiated at Sector Perform by RBC Capital with $330 target
RBC Capital has initiated coverage on Cencora Inc (NYSE:COR) with a Sector Perform rating and a price target of $330. The firm notes Cencora's strong position in specialty pharma but suggests it lacks the high-growth, high-margin businesses of some competitors, reflected in its approximately 4% gross profit margin. Despite potential headwinds from IRA negotiations affecting Part B drugs, RBC Capital anticipates biosimilar introductions will contribute positively to operating income.
Narravero Named a Market Shaper in the 2026 Gartner® Emerging Market Quadrant for Digital Product Passport
Narravero has been recognized as a Market Shaper in the 2026 Gartner® Emerging Market Quadrant for Digital Product Passport - Established Vendors. The company's platform focuses on interoperability with global data standards and uses AI to streamline DPP implementation and scaling, reducing manual data work. Narravero emphasizes that Digital Product Passports are evolving beyond mere compliance to become strategic product data infrastructure for businesses.
Cencora stock initiated at Sector Perform by RBC Capital with $330 target
RBC Capital has initiated coverage on Cencora Inc (NYSE:COR) with a Sector Perform rating and a price target of $330. The firm believes Cencora's pharma-aligned platform will benefit from specialty pharma growth but notes it lacks the high-growth, high-margin businesses seen in competitors. Despite potential headwinds from IRA negotiations on Part B drugs, biosimilar introductions are expected to drive margin accretion.
Deutsche Bank AG Purchases Shares of 1,013,049 Cencora, Inc. $COR
Deutsche Bank AG has acquired a new position in Cencora, Inc. (NYSE:COR), purchasing 1,013,049 shares valued at approximately $286.67 million during the second quarter. This move makes Deutsche Bank AG one of several institutional investors increasing their stakes in Cencora, which currently holds an average analyst rating of "Moderate Buy" with a consensus price target of $374.25. The company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.60 per share, alongside a $2 billion share buyback program.
Cencora stock initiated at Sector Perform by RBC Capital with $330 target
RBC Capital initiated coverage on Cencora Inc (NYSE: COR) with a Sector Perform rating and a $330 price target, noting the company's pharma-aligned platform benefits from specialty pharma growth. Despite a 4% gross profit margin, RBC Capital expects specialty drugs to drive pharma spending to over 55% by 2028, with new cell and gene therapies contributing significantly. The firm anticipates headwinds from IRA negotiations on Part B drugs, but biosimilar introductions are expected to boost operating income.
Cencora stock initiated at Sector Perform by RBC Capital with $330 target
RBC Capital has initiated coverage on Cencora Inc (NYSE:COR) with a Sector Perform rating and a price target of $330.00, citing the company's pharma-aligned platform benefiting from growth in specialty pharma. While acknowledging the growth potential, RBC Capital expressed concerns about Cencora's gross profit margin and its lack of differentiated high-growth, high-margin businesses compared to competitors. Despite potential headwinds from IRA negotiations, the firm anticipates biosimilar introductions to boost operating income, and recent strong fiscal Q3 2026 results show Cencora surpassing expectations and raising its full-year profit outlook.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) stock rose 1.16% to $316.13 on Tuesday, outperforming the broader market which saw the S&P 500 Index (SPX) fall 0.69% and the Dow Jones Industrial Average (DJIA) fall 0.22%. Despite the gain, the stock remains 16.27% below its 52-week high.
Occidental Asset Management LLC Purchases Shares of 20,097 Cencora, Inc. $COR
Occidental Asset Management LLC recently acquired 20,097 shares of Cencora, Inc. (NYSE:COR) valued at approximately $5.7 million, marking a new stake in the company. Institutional investors now collectively own 97.52% of Cencora. The company reported strong quarterly earnings, exceeding analyst expectations for both EPS and revenue, and has a "Moderate Buy" consensus rating from analysts with an average price target of $374.25.
JMID Dividend: 0.54% Yield, $0.18/Share — History & Dates
This article details the dividend history and yield for Janus Henderson Mid Cap Growth Alpha ETF (JMID). It highlights that JMID offers a 0.55% dividend yield, paying $0.18 per share annually, with a payout ratio of 0.43. The ETF has been paying dividends since 2024 and boasts a 5-year dividend growth rate of 32.87%.
TimesSquare Capital Management LLC Acquires Shares of 418,087 Cencora, Inc. $COR
TimesSquare Capital Management LLC recently acquired 418,087 shares of Cencora, Inc. (NYSE:COR), valued at approximately $118.31 million, making it their 11th largest holding. Other institutional investors have also adjusted their positions in Cencora, and analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $374.25. The company recently reported strong quarterly earnings, beating estimates, and declared a quarterly dividend of $0.60 per share, alongside a $2.00 billion share buyback plan.
OneDigital Investment Advisors LLC Makes New $1.57 Million Investment in Cencora, Inc. $COR
OneDigital Investment Advisors LLC has made a new $1.57 million investment in Cencora, Inc. (NYSE:COR), acquiring 5,561 shares. Institutional investors collectively own a significant 97.52% of the company, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $374.25. Cencora recently exceeded quarterly earnings and revenue expectations, authorized a $2 billion share repurchase program, and declared a quarterly dividend of $0.60 per share.
Flputnam Investment Management Co. Makes New $1.90 Million Investment in Cencora, Inc. $COR
Flputnam Investment Management Co. has made a new $1.90 million investment in Cencora, Inc. by purchasing 6,711 shares. Cencora recently exceeded its quarterly earnings and revenue expectations, reported a 5.1% year-over-year revenue increase, and authorized a $2 billion share-repurchase plan along with a $0.60 per share quarterly dividend. Analysts currently maintain a "Moderate Buy" consensus rating for the company with an average price target of $374.25.
Peachtree Investment Partners LLC Buys New Position in Cencora, Inc. $COR
Peachtree Investment Partners LLC has acquired a new stake in Cencora, Inc. (NYSE:COR), purchasing 7,789 shares valued at approximately $2.204 million, making it 0.7% of their investment portfolio. Other institutional investors also modified their holdings, and 97.52% of Cencora's stock is owned by institutions and hedge funds. The company recently reported strong quarterly earnings, announced a $2 billion stock buyback program, and declared a quarterly dividend of $0.60 per share.
8,351 Shares in Cencora, Inc. $COR Bought by Global Retirement Partners LLC
Global Retirement Partners LLC has acquired a new stake of 8,351 shares in Cencora, Inc. (NYSE:COR), valued at approximately $2.36 million, according to its latest SEC filing. This acquisition is part of broader institutional investor activity, with 97.52% of Cencora's stock now owned by hedge funds and other institutional investors. The article also details Cencora's recent financial performance, stock buyback plan, dividend announcement, and analyst ratings, indicating a "Moderate Buy" consensus.
Cencora Raises 2026 EPS Outlook as Quarterly Profit Climbs
Cencora Inc. has raised its fiscal 2026 earnings outlook after reporting a 5.1% increase in third-quarter revenue to $84.8 billion and a 29% climb in operating income. The pharmaceutical distributor now expects adjusted diluted earnings of $17.75 to $17.95 per share, driven by growth in pharmaceutical distribution, specialty products, and the acquired OneOncology business. The company also accelerated capital returns, repurchasing $1 billion of stock during the quarter.
Cencora Inc (HAM:ABG) Stock Price & 30 Year Financial Data
This article provides detailed financial data for Cencora Inc (HAM:ABG), including its stock price, market capitalization, enterprise value, and various growth rates over 1, 5, and 10-year periods. It highlights key financial metrics such as revenue, EPS, EBIT, EBITDA, free cash flow, and dividends, along with disclaimers regarding data accuracy and investment advice. The data is presented with options for viewing annual or quarterly trends and exporting.
Do Strong Q3 Results And Bigger Credit Lines Change The Bull Case For Cencora (COR)?
Cencora (COR) recently reported strong Q3 2026 results with $84.75 billion in sales and $763.52 million in net income, alongside declaring a $0.60 quarterly dividend. The company also expanded its multi-currency credit facility to $7.00 billion with maturities extended to 2031, reinforcing its financial flexibility. These developments support Cencora's investment narrative focused on scale in pharmaceutical distribution and disciplined capital allocation, even as analysts remain cautious about potential margin pressures and execution risks in specialty services.
Do Strong Q3 Results And Bigger Credit Lines Change The Bull Case For Cencora (COR)?
Cencora (COR) recently reported strong Q3 2026 results with US$84.75 billion in sales and US$763.52 million net income, alongside a US$0.60 quarterly dividend. The company also expanded its multi-currency revolving credit facility to US$7.00 billion, extending maturities to 2031, which reinforces its ability to fund operations, acquisitions, and shareholder returns. While these actions support the existing bull case, the article highlights ongoing concerns about margin pressure from lower fee products and execution risks in specialty services.
Summit Global Investments Buys Shares of 8,066 Cencora, Inc. $COR
Summit Global Investments acquired 8,066 shares of Cencora, Inc. (NYSE:COR) for approximately $2.28 million during the second quarter. Cencora maintains a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $374.25, and institutional investors own 97.52% of the company. The company recently exceeded earnings and revenue expectations, declared a $0.60 quarterly dividend, and authorized a $2 billion share repurchase program.
Bryn Mawr Trust Advisors LLC Takes $934,000 Position in Cencora, Inc. $COR
Bryn Mawr Trust Advisors LLC has acquired a new position in Cencora, Inc. (NYSE:COR), purchasing 3,301 shares valued at approximately $934,000. This move is part of broader institutional activity, with several other firms also adjusting their stakes in the pharmaceutical distribution company. Cencora recently reported strong earnings, topping analyst estimates, and announced a stock repurchase plan and a quarterly dividend.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) saw its stock advance by 1.43% to $313.82 on Friday, bucking the broader market trend where the S&P 500 and Dow Jones Industrial Average both experienced declines. This rise broke a two-day losing streak for Cencora.
If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today
Cencora (NYSE: COR) has significantly outperformed the market over the last decade, with an average annual return of 19.83%. An initial investment of $1000 in COR stock ten years ago would now be worth $6,070.40, highlighting the power of compounded returns. The company currently holds a market capitalization of $59.16 billion.
Cencora: Walgreens Volume Disruption Raises New Concern, but We Make No Changes for Now
Cencora disclosed that a portion of the volume it serviced for Walgreens began moving elsewhere starting July 1, causing a 4% drop in shares. Despite this new concern, the company reaffirmed its full-year EPS guidance of $17.75-$17.95, and Morningstar analysts are not yet making changes to their ratings. The article notes this development while referring to previous positive reports on Cencora's growth rebound and strong specialty assets.
Surging Sales, Falling EPS, and Big Buybacks Could Be A Game Changer For McKesson (MCK)
McKesson (MCK) reported a first-quarter sales increase to US$105.38 billion, while net income and diluted EPS decreased. The company significantly reduced its share count by repurchasing 3.6 million shares for US$2.896 billion, completing a long-running US$29 billion buyback authorization. This combination of higher sales, lower earnings, and substantial buybacks is reshaping McKesson's capital allocation and reinforces management's strategy of returning cash to shareholders amidst policy risks and competitive pressures.
Cencora Inc. stock underperforms Wednesday when compared to competitors
Cencora Inc. (COR) stock fell by 5.90% to $314.17 on Wednesday, underperforming the broader market. This drop occurred despite the S&P 500 Index seeing a slight gain, while the Dow Jones Industrial Average experienced a marginal decline. The stock's fall ended a two-day winning streak for Cencora.
Cencora Inc Stock (COR) Closed Down by 5.92% on Aug 12: Key Drivers Unveiled
Cencora Inc (COR) stock closed down by 5.92% on August 12, primarily due to the confirmed transition of non-prime Walgreens pharmaceutical volume to competitors. Despite management reiterating full-year earnings per share guidance, investors focused on potential revenue risks and customer retention challenges in the competitive pharmaceutical distribution market. The company also faces headwinds from subdued revenue guidance, rising interest expenses, and asset impairments, overshadowing its industry-leading annual revenue of $321.33 billion.
Cencora reaffirms $17.75-$17.95 FY26 EPS guidance amid Walgreens shift
Cencora confirmed that some Walgreens volume will shift outside its operations starting July 1, 2026, but its primary vendor agreement with Walgreens remains unaffected. The company reiterated its fiscal year 2026 adjusted diluted EPS guidance of $17.75-$17.95, stating that this change was already factored into previous Q4 expectations. This decision indicates the stability of its financial outlook despite the operational adjustment.
Cencora Reports Walgreens Volume Transition, Confirms FY2026 Adjusted EPS Forecast
Cencora, Inc. has reported to the SEC that some Walgreens volume began transitioning out of the company on July 1, 2026, a move that was fully anticipated and does not affect their prime vendor agreement with Walgreens. The company reconfirmed its adjusted diluted EPS guidance for fiscal year 2026, setting it between $17.75 and $17.95. This disclosure emphasizes that while a portion of the business is shifting, the core relationship with Walgreens remains strong, and the financial outlook is unchanged.
Cencora says certain Walgreens volume moves outside company; reaffirms FY26 adjusted EPS $17.75-$17.95
Cencora announced that certain Walgreens volume began moving outside the company as of July 1, 2026. Despite this change, the prime vendor agreement with Walgreens, which represents the majority of Cencora's Walgreens business, remains unchanged. Cencora reaffirmed its fiscal year 2026 adjusted diluted EPS guidance of $17.75 to $17.95, stating this outcome was anticipated in their August 5, 2026 commentary.
Cencora dips on loss of some Walgreens business (COR:NYSE)
Cencora's shares experienced a decline in afternoon trading after the medical distributor announced the loss of some business operations previously serving the Walgreens pharmacy chain. The company, formerly known as AmerisourceBergen, stated that certain business activities are moving outside their previous arrangement. This development impacted investor confidence, leading to the stock dip.
Cencora maintains earnings guidance as some Walgreens volume moves away
Cencora (NYSE:COR) announced that some Walgreens volume previously serviced outside of its prime vendor agreement has shifted away, effective July 1. Despite this change, which was anticipated, the company reaffirmed its adjusted diluted earnings per share guidance of $17.75 to $17.95 for fiscal year 2026. Cencora also recently surpassed Wall Street forecasts with strong Q3 2026 results, reporting adjusted earnings of $4.48 per share and revenue of $84.8 billion, leading to a raised profit outlook for the full year.
Cencora maintains earnings guidance as some Walgreens volume moves away
Cencora announced that some Walgreens volume not covered by its prime vendor agreement has begun to shift away, a move it had anticipated. Despite this change, the company reaffirmed its adjusted diluted earnings per share guidance of $17.75 to $17.95 for fiscal year 2026. This follows Cencora's strong fiscal third-quarter performance, where it exceeded Wall Street forecasts and raised its full-year profit outlook.
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026
Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in Q3 2026, supported by positive human factors and pharmacokinetic study results, and is preparing for a potential launch focusing on allergists. Aquestive maintained its full-year 2026 revenue guidance of $46 million to $50 million.
Wedge Capital Management L L P NC Increases Position in Cencora, Inc. $COR
Wedge Capital Management L L P NC has increased its stake in Cencora, Inc. (NYSE:COR) by 31.0% during the second quarter, bringing its total holdings to 105,614 shares valued at approximately $29.9 million. Institutional investors and hedge funds collectively own 97.52% of the company's stock. Cencora has reported strong financials, beating earnings expectations with $4.48 adjusted EPS on $84.75 billion in revenue, and analysts maintain a "Moderate Buy" rating with an average price target of $374.25.
Insight Wealth Strategies LLC Purchases 6,648 Shares of Cencora, Inc. $COR
Insight Wealth Strategies LLC increased its stake in Cencora, Inc. by 37.6% in the second quarter, adding 6,648 shares. Institutional investors hold 97.52% of the company, and analysts have a "Moderate Buy" consensus with an average price target of $374.25. Cencora also surpassed earnings and revenue expectations, reported a quarterly dividend of $0.60 per share, and authorized a $2 billion share-buyback program.
Cencora, Inc. (NYSE:COR) Given Average Rating of "Moderate Buy" by Brokerages
Cencora, Inc. (NYSE:COR) has received a consensus "Moderate Buy" rating from fifteen brokerage firms, with an average 12-month price target of $374.25. The company recently surpassed quarterly earnings expectations, reporting $4.48 in adjusted EPS and $84.75 billion in revenue. Cencora also authorized a $2 billion share repurchase program and declared a quarterly dividend of $0.60 per share.
CENCORA INC. : WELLS FARGO RAISES TARGET PRICE TO $395 FROM $331
Wells Fargo has increased its target price for Cencora Inc. from $331 to $395. This news was reported by Reuters and indicates a positive outlook from the financial institution on Cencora's future performance. The article itself provides minimal detail beyond this price target adjustment.
McKesson (MCK) Earnings And Buybacks Keep Fair Value In Focus
McKesson (MCK) recently reported Q1 results showing higher sales but lower net income and EPS year-over-year, alongside an update on its share repurchase program. The stock has seen significant returns over the past year, prompting investors to consider its fair value, which Simply Wall St estimates at $980.80, suggesting it is undervalued compared to its current price of around $901. The narrative attributes this to increased adoption of specialty pharmaceuticals and recent acquisitions, though potential policy pressures on drug pricing remain a risk.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) stock rose 2.73% to $333.87 on Tuesday, outperforming the broader market which saw the S&P 500 and Dow Jones Industrial Average both decline. This marks the second consecutive day of gains for Cencora.
